CHAPEL HILL, N.C., Oct. 4, 2016 /PRNewswire/ -- TARGET PharmaSolutions, Inc. is pleased to announce the launch of TARGET-PBC (Primary Biliary Cholangitis). TARGET-PBC is a collaborative platform created to advance the understanding of real world treatment patterns in PBC. Intercept Pharmaceuticals, Inc. (ICPT) has formed a collaboration with TARGET-PBC.
“TARGET-PBC represents a unique opportunity in the study of this rare disease. By fostering collaborations with academic centers and community clinical practices and scientifically overseen by a Steering Committee comprised of leading PBC researchers, TARGET-PBC will answer crucial questions involving the safety and efficacy of approved and off-label therapies used in the real world and will identify at-risk populations in need of novel therapies,” said Cynthia Levy, MD, Associate Professor of Medicine at the University of Miami and Chair of the TARGET-PBC Steering Committee.
“We have seen tremendous progress in PBC research over the last several years, but there are still many critical gaps in our understanding of this disease that must be addressed,” said Juan Carlos Lopez-Talavera, MD, Ph.D., Senior Vice President of Medical Affairs at Intercept. “TARGET-PBC will create a powerful new stream of Real World Data to enhance our understanding of the natural history of PBC, unmet need and ultimately help us refine our treatment strategies to improve care for patients.”
TARGET-PBC provides access to a biorepository linked to validated clinical outcomes, including patient reported outcomes, putting TARGET-PBC in a very unique place amongst typical patient registries. With a goal to enroll up to 1500 patients with PBC, at 30 different sites across the US, new industry partners will be provided an entire platform of data and information that can be used to truly advance the entire field.
TARGET PharmaSolutions was formed in February 2015 and currently has four disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), and TARGET-IBD (inflammatory bowel disease). The TARGET model is based on the success of HCV-TARGET, a case study in Hepatitis C. Formed in 2011 by Drs. Michael Fried, MD (University of North Carolina) and David Nelson, MD (University of Florida), HCV-TARGET has enrolled over 10,000 patients and has generated data that has been used by physicians, payers, and regulatory agencies around the world.
About TARGET PharmaSolutions
TARGET PharmaSolutions is a privately held clinical data company that provides pharmaceutical and biotechnology partners a more efficient way to generate data that can be used to better understand the natural history of diseases, including treatment outcomes in the real world setting. TARGET PharmaSolutions is based in Chapel Hill, N.C. For more information, visit www.targetpharmasolutions.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/target-pharmasolutions-announces-the-launch-of-target-pbc-primary-biliary-cholangitis-300338690.html
SOURCE TARGET PharmaSolutions, Inc.
